Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
For full access to this article login to GEN Select now.
Long-Term Viability in a Down Market
Suppliers Need to Focus on the Future Even if It Means Temporarily Reducing Sales Volumes
- Research and drug discovery always involve a compromise. Even in the best of times, a balancing of competing interests associated with cost, speed, accuracy, and relevance is required. After a period of expansive opportunities and extensive growth, the life sciences are facing an economic landscape that has fundamentally ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.